Clinical study of advanced glycation end products in Egyptian diabetic obese and non-obese patients

International Journal of Biomedical Science

Volumn 7, Issue 3, 2011, Pages 191-200

  Amin, Mohamed N ^a   Mosa, Amany A ^b   El Shishtawy, Mamdouh M ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Advanced glycation end products; Carboxymethyllysine; Obesity and type 2 diabetes mellitus; Receptors for advanced glycation end products

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; HEMOGLOBIN A1C; LIPID; SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CLINICAL STUDY; CONTROLLED STUDY; EGYPT; FEMALE; HUMAN; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; WAIST HIP RATIO;

EID: 80054051876     PISSN: 15509702     EISSN: 15552810     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis. 2008; 196 (1): 9-21.
2. Ahmed N. Advanced glycation endproducts: role in pathology of diabetic complications. Diabetes. Res. Clin. Pract. 2005; 67 (1): 3-21.
3. Drinda S, Franke S, Canet CC, Petrow P, et al. Identification of the advanced glycation end products N (epsilon)-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis. Ann. Rheum. Dis. 2002; 61 (6): 488-492.
4. Ramasamy R, Vannucci S.J, Yan SS, Herold K, et al. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 2005; 15 (7): 16R-28R.
5. Vincent AM, Perrone L, Sullivan KA, Backus C, et al. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology. 2007; 148 (2): 548-558.
6. Hein GE. Glycation end products in osteoporosis Is there a patho-physiologic importance? Clinica. Chimica. Acta. 2006; 371: 32-36.
7. Schmidt AM,Stern DM. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol. Metab. 2000; 11 (9): 368-375.
8. World Health Organisation. Physical status: the use and interpretation of anthropometry: report of a WHO Expert Comittee. World Health Organ. Tech. Rep. Ser. 1995; 854: 1-452.
9. Coutinho T, Goel K, Corrêa de Sá D, Kragelund C, et al. Central obesity and survival in subjects with coronary artery disease a systematic review of the literature and collaborative analysis with individual subject data. J. Am. Coll. Cardiol.2011; 57 (19): 1877-1886.
10. James TM, Davis JE, McDonald JM, Santiago JV, et al. Comparison of hemoglobin A1c and hemoglobin A1 in diabetic patients. Clin. Biochem. 1981; 14 (1): 25-27.
11. Trinder P. Determination of blood glucose using 4-amino phenazone as oxygen acceptor. J. Clin. Pathol. 1969; 22 (2): 246.
12. Richmond W. Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin. Chem. 1973; 19 (12): 1350-1356.
13. Trinder P. Triglycerides estimation by GPO-PAP method. Ann. Clin. Biochem. 1969; 6 (2): 24-27.
14. Izawa S, Okada M, Matsui H, Horita Y. A New direct method for measuring HDL cholesterol which does not produce any biased values. J. Med. Pharm. Sci. 1997; 37: 1385-1388.
15. Schumann G, Bonora R, Ceriotti F, Férard G, et al. IFCC primary reference procedure for the measurement of catalytic activity concentrations of enzymes at 37°C. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clin. Chem. Lab. Med. 2002; 40 (7): 718-724.
16. Schumann G, Bonora R, Ceriotti F, Férard G, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 5. Reference procedure for the measurement of catalytic concentration of aspartate aminotransferase. Clin. Chem. Lab. Med. 2002; 40 (7): 725-733.
17. Doumas BT, Watson WA, Biggs HG. Albumin standards and measurement of serum albumin with bromcresol green. Clin. Chim. Acta. 1971; 31 (1): 87-96.
18. Larsen K. Creatinine assay by a reaction-kinetic principle. Clin. Chim. Acta. 1972; 41: 209-217.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972; 18 (6): 499-502.
20. Schleicher ED, Wagner E, Nerlich A. G. Increased accumulation of the glycoxidation product Nε(carboxymethyl) lysine in human tissues in diabetes and aging. J. Clin. Invest. 1997; 99 (3): 457-468.
21. Norata GD, Garlaschelli K, Grigore L, Tibolla G, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr. Metab. Cardiovasc. Dis. 2009; 19 (2): 129-134.
22. Akehi Y, Anzai K, Katsuta H, Yoshida R, et al. Adverse effects of obesity on β-cell function in Japanese subjects with normal glucose tolerance. Obes. Res. Clin. Pract. 2008; 2 (3): 195-202.
23. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol. Behav. 2008; 94 (2): 206-218.
24. Swiatkowska-Stodulska R, Babińska A, Skibowska-Bielińska A, Sworczak K. Assessment of α1-antitrypsin and α2-macroglobulin levels in obese patients. Pol. Arch. Med. Wewn. 2008; 118 (12): 713-717.
25. Gokalp D, Bahceci M, Ozmenb S, Arikana S, et al. Adipocyte volumes and levels of adipokines in diabetes and obesity. Diab Metab Syn: Clin. Res. Rev. 2008; 2 (4): 253-258.
26. Ai M, Otokozawa S, Schaefer EJ, Asztalos BF, et al. Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus. Clin. Chim. Acta. 2009; 406 (1-2): 71-74.
27. Youn BS, Klöting N, Kratzsch J, Lee N, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008; 57 (2): 372-373.
28. Koga M, Otsuki M, Matsumoto S, Saito H, et al. Negative association of obesity and its related chronic inflammation with serum glycated albumin but not glycated hemoglobin levels. Clin. Chim. Acta. 2007; 378 (1-2): 48-52.
29. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet. 2005; 366 (9491): 1059-1062.
30. Betteridge DJ. Diabetic dyslipidaemia. Eur. J. Clin. Invest. 1999; 29 (2): 12-16.
31. Valerio G, Licenziati MR, Iannuzzi A, Franzese A, et al. Insulin resistance and impaired glucose tolerance in obese children and adolescents from Southern Italy. Nutr. Metab. Cardiovasc. Dis. 2006; 16 (4): 279-284.
32. Sikaris KA. The clinical biochemistry of obesity-more than skin deep. Heart Lung Circ. 2007; 16 (3): S45-S50.
33. Quilliot D, Zannad F, Ziegler O. Impaired response of cardiac autonomic nervous system to glucose load in severe obesity. Metabolism. 2005; 54 (7): 966-974.
34. Nakatsuji H, Kishida K, Kitamura T, Nakajima C, et al. Dysregulation of glucose, insulin, triglyceride, blood pressure, and oxidative stress after an oral glucose tolerance test in men with abdominal obesity. Metabolism. 2010; 59 (4): 520-526.
35. Chrysohoou C, Panagiotakos DB, Pitsavos C, Skoumas I, et al. The implication of obesity on total antioxidant capacity in apparently healthy men and women: The ATTICA study. Nutr. Metab. Cardiovasc. Dis. 2007; 17 (8): 590-597.
36. Yamagishi S, Adachi H, Nakamura K, Matsui T, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism. 2006; 55 (9): 1227-1231.
37. Saisho Y, Maruyama T, Hirose H, Saruta T. Relationship between proinsulin-to-insulin ratio and advanced glycation end products in Japanese type 2 diabetic subjects. Diabetes Res. Clin. Pract. 2007; 78 (2): 182-188.
38. Nakamura K, Yamagishi S, Adachi H, Matsui T, et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc. Res. 2008; 76 (1): 52-56.
39. Grossin N, Wautier MP, Meas T, Guillausseau PJ, et al. Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab. 2008; 34 (4 Pt 1): 392-395.
40. Boor P, Celec P, Behuliak M, Grancic P, et al. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats. Metabolism. 2009; 58 (11): 1669-1677.
41. Semba RD, Najjar SS, Sun K, Lakatta EG, et al. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am. J. Hypertens. 2009; 22 (1): 74-79.
42. Miyashita Y, Nishimura R, Morimoto A, Matsudaira T, et al. Glycated albumin is low in obese, type 2 diabetic patients. Diabetes Res. Clin. Pract. 2007; 78 (1): 51-55.
43. Folsom AR, Ma J, Eckfeldt JH, Nieto FJ, et al. Low serum albumin association with diabetes mellitus and other cardiovascular risk factors but not with prevalent cardiovascular disease or carotid artery intimamedia thickness. Ann. Epidemiol. 1995; 5 (3): 186-191.
44. Rossi MC, Nicolucci A, Pellegrini F, Comaschi M, et al. Obesity and changes in urine albumin/Creatinine ratio in patients with type 2 diabetes: The DEMAND Study. Nutr. Metab. Cardiovasc. Dis. 2010; 20 (2): 110-116.
45. Jerums G, Premaratne E, Panagiotopoulos S, Clarke S, et al. New and old markers of progression of diabetic nephropathy. Diabetes Res. Clin. Pract. 2008; 82 (1): s30-s37.
46. Lee IT, Huang CN, Lee WJ, Lee HS, et al. Aggravation of albuminuria by metabolic syndrome in type 2 diabetic Asian subjects. Diabetes Res. Clin. Pract. 2008; 81 (3): 345-350.
47. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol. 2005; 25 (5): 1032-1037.
48. Geroldi D, Falcone C, Emanuele E, D'Angelo A, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J. Hypertens. 2005; 23 (9): 1725-1729.